keyword
Keywords prostate cancer, prognostic ma...

prostate cancer, prognostic markers

https://read.qxmd.com/read/38643469/aat-resistance-related-ac007405-2-and-al354989-1-as-novel-diagnostic-and-prognostic-markers-in-prostate-cancer
#1
JOURNAL ARTICLE
Yuanzhong Deng, Chunlin Zhang, Haitao Yu, Guo Chen, Xiang Peng, Yang Li, Zhenwei Feng, Wei Shi, Xuesong Bai, Xin Gou, Nian Liu
OBJECTIVE: Prostate cancer (PCa) is the second disease threatening men's health, and anti-androgen therapy (AAT) is a primary approach for treating this condition. Increasing evidence suggests that long non-coding RNAs (lncRNAs) play crucial roles in the development of PCa and the process of AAT resistance. The objective of this study is to utilize bioinformatics methods to excavate lncRNAs association with AAT resistance and investigate their biological functions. METHODS: AAT resistance-related risk score model (ARR-RSM) was established by multivariate Cox analysis...
April 19, 2024: Aging
https://read.qxmd.com/read/38643190/endoplasmic-reticulum-stress-related-genes-as-prognostic-and-immunogenic-biomarkers-in-prostate-cancer
#2
JOURNAL ARTICLE
Lilin Wan, Yunxia Fan, Tiange Wu, Yifan Liu, Ruixin Zhang, Saisai Chen, Chenggui Zhao, Yifeng Xue
BACKGROUND: The metastasis and aggressive nature of prostate cancer (PCa) has become a major malignancy related threat that concerns men's health. The efficacy of immune monotherapy against PCa is questionable due to its lymphocyte-suppressive nature. METHOD: Endoplasmic reticulum stress- (ERS-) and PCa-prognosis-related genes were obtained from the Molecular Signatures Database and the Cancer Genome Atlas database. The expression, prognosis and immune infiltration values of key genes were explored by "survival R package", "rms", "xCELL algorithm", and univariate-multivariate Cox and LASSO regression analyses...
April 20, 2024: European Journal of Medical Research
https://read.qxmd.com/read/38634185/identification-of-functional-and-diverse-circulating-cancer-associated-fibroblasts-in-metastatic-castration-na%C3%A3-ve-prostate-cancer-patients
#3
JOURNAL ARTICLE
Richell Booijink, Leon W M M Terstappen, Eshwari Dathathri, Khrystany Isebia, Jaco Kraan, John Martens, Ruchi Bansal
In prostate cancer (PCa), cancer-associated fibroblasts (CAFs) promote tumor progression, drug resistance, and metastasis. Although circulating tumor cells are studied as prognostic and diagnostic markers, little is known about other circulating cells and their association with PCa metastasis. Here, we explored the presence of circulating CAFs (cCAFs) in metastatic castration-naïve prostate cancer (mCNPC) patients. cCAFs were stained with fibroblast activation protein (FAP), epithelial cell adhesion molecule (EpCAM), and receptor-type tyrosine-protein phosphatase C (CD45), then FAP+ EpCAM- cCAFs were enumerated and sorted using fluorescence-activated cell sorting...
April 17, 2024: Molecular Oncology
https://read.qxmd.com/read/38627732/significance-of-psca-as-a-novel-prognostic-marker-and-therapeutic-target-for-cancer
#4
REVIEW
Tina Nayerpour Dizaj, Abolfazl Doustmihan, Behnaz Sadeghzadeh Oskouei, Morteza Akbari, Mehdi Jaymand, MirAhmad Mazloomi, Rana Jahanban-Esfahlan
One of the contributing factors in the diagnosis and treatment of most cancers is the identification of their surface antigens. Cancer tissues or cells have their specific antigens. Some antigens that are present in many cancers elicit different functions. One of these antigens is the prostate stem cell antigen (PSCA) antigen, which was first identified in the prostate. PSCA is a cell surface protein that has different functions in different tissues. It can play an inhibitory role in cell proliferation as well as a tumor-inducing role...
April 16, 2024: Cancer Cell International
https://read.qxmd.com/read/38615487/nlr-outperforms-low-hemoglobin-and-high-platelet-count-as-predictive-and-prognostic-biomarker-in-metastatic-renal-cell-carcinoma-treated-with-immune-checkpoint-inhibitors
#5
JOURNAL ARTICLE
Matthew Young, Jose C Tapia, Bernadett Szabados, Agne Jovaisaite, Francesca Jackson-Spence, Elizabeth Nally, Thomas Powles
BACKGROUND: Reliable biomarkers in renal cell carcinoma (RCC) remain elusive. While several markers have been shown to be associated with prognosis, and may aid in risk assessment, predictive biomarkers of response to immune checkpoint inhibitors (ICIs) have not been established. Previous studies have shown that a high pretreatment neutrophil-lymphocyte ratio (NLR) is a negative prognostic factor in RCC. However, a clinically useful cut-off for the predictive and prognostic value of NLR has not been well defined...
March 8, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38587547/impact-of-circulating-tumor-cell-expressed-prostate-specific-membrane-antigen-and-prostate-specific-antigen-transcripts-in-different-stages-of-prostate-cancer
#6
JOURNAL ARTICLE
Hyungseok Cho, Seok-Soo Byun, Nak-Hoon Son, Jae Il Chung, Won Ik Seo, Chan Ho Lee, Todd M Morgan, Ki-Ho Han, Jae-Seung Chung
PURPOSE: Prostate-specific membrane antigen (PSMA)-based images, which visually quantify PSMA expression, are used to determine prostate cancer micrometastases. This study evaluated whether a circulating tumor cell (CTC)-based transcript platform, including PSMA mRNA, could help identify potential prognostic markers in prostate cancer. EXPERIMENTAL DESIGN: We prospectively enrolled 21 healthy individuals and 247 patients with prostate cancer [localized prostate cancer (LPCa), n = 94; metastatic hormone-sensitive prostate cancer (mHSPC), n = 44; and metastatic castration-resistant prostate cancer (mCRPC), n = 109]...
April 8, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38586315/microrna-21-and-long-non-coding-rnas-interplays-underlie-cancer-pathophysiology-a-narrative-review
#7
REVIEW
Roberta Giordo, Fatemeh Abdullah M Ahmadi, Nedal Al Husaini, Noora Rashid A M Al-Nuaimi, Salma M S Ahmad, Gianfranco Pintus, Hatem Zayed
Non-coding RNAs (ncRNAs) are a diverse group of functional RNA molecules that lack the ability to code for proteins. Despite missing this traditional role, ncRNAs have emerged as crucial regulators of various biological processes and have been implicated in the development and progression of many diseases, including cancer. MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are two prominent classes of ncRNAs that have emerged as key players in cancer pathophysiology. In particular, miR-21 has been reported to exhibit oncogenic roles in various forms of human cancer, including prostate, breast, lung, and colorectal cancer...
September 2024: Non-Coding RNA Research
https://read.qxmd.com/read/38585861/cdhu40-a-novel-marker-gene-set-of-neuroendocrine-prostate-cancer-nepc
#8
Sheng Liu, Hye Seung Nam, Ziyu Zeng, Xuehong Deng, Elnaz Pashaei, Yong Zang, Lei Yang, Chenglong Li, Jiaoti Huang, Michael K Wendt, Xin Lu, Rong Huang, Jun Wan
UNLABELLED: Prostate cancer (PCa) is the most prevalent cancer affecting American men. Castration-resistant prostate cancer (CRPC) can emerge during hormone therapy for PCa, manifesting with elevated serum prostate-specific antigen (PSA) levels, continued disease progression, and/or metastasis to the new sites, resulting in a poor prognosis. A subset of CRPC patients shows a neuroendocrine (NE) phenotype, signifying reduced or no reliance on androgen receptor (AR) signaling and a particularly unfavorable prognosis...
March 31, 2024: bioRxiv
https://read.qxmd.com/read/38581330/arginase-2-is-a-diagnostic-and-prognostic-marker-for-prostate-cancer-and-is-associated-with-metabolism
#9
JOURNAL ARTICLE
Jianxin Li, Yu Zheng, Chaojiang Chen, Zhuoyuan Lin, Jiangang Pan, Yuxiang Liang, Funeng Jiang, Minyao Jiang, Xing Zhou, Weide Zhong
OBJECTIVE: Metabolism, a basic need and biochemical process for cell survival and proliferation, is closely connected with the pathogenesis and progression of prostate cancer. METHODS: A four-gene signature construct that includes CKM (CKM), CD38, Enoyl Coenzyme A(EHHADH), and Arginase 2(ARG2) was created by bioinformatics. Finally, hub genes were validated by IHC and in vitro experiments. RESULTS: The results showed the AUCs of the logistic regression and neural networks diagnostic model for the diagnosis of two subtypes were 0...
April 5, 2024: Alternative Therapies in Health and Medicine
https://read.qxmd.com/read/38560743/understanding-the-utility-of-less-than-six-month-prognosis-using-administrative-data-among-u-s-nursing-home-residents-with-cancer
#10
JOURNAL ARTICLE
Long Vu, Siran M Koroukian, Sara L Douglas, Hannah L Fein, David F Warner, Nicholas K Schiltz, Jennifer Cullen, Cynthia Owusu, Martha Sajatovic, Johnie Rose, Richard Martin
BACKGROUND: There is a dearth of studies evaluating the utility of reporting prognostication among nursing home (NH) residents with cancer. OBJECTIVE: To study factors associated with documented less than six-month prognosis, and its relationship with end-of-life (EOL) care quality measures among residents with cancer. METHODS: The Surveillance, Epidemiology, and End Results linked with Medicare, and the Minimum Data Set databases was used to identify 20,397 NH residents in the United States with breast, colorectal, lung, pancreatic, or prostate cancer who died between July 2016 and December 2018...
2024: Palliative medicine reports
https://read.qxmd.com/read/38552037/is-fibroblast-growth-factor-11-fgf11-a-predictive-marker-for-breast-cancer
#11
JOURNAL ARTICLE
Selin Aktürk Esen, Sefika Karabulut, Muge Buyukaksoy, Gulnaz Kurt Cevik, Furkan Ceylan, Burak Civelek, Mehmet Ali Nahit Şendur, Fazli Erdogan, Doğan Uncu
The prognostic role of fibroblast growth factor 11 (FGF11) has only been reported in cancers such as nasopharyngeal carcinoma and prostate cancer. The role of FGF11 in breast cancer is not fully known. It was aimed to compare FGF11 expression levels in de novo metastatic hormone receptor-positive, human epidermal reseptor-2-negative breast tumor tissue and healthy breast tissue and investigate the effect of the FGF11 expression on survival in breast cancer patients. To determine the FGF11 expression rate, breast tumor tissue of breast cancer patients diagnosed by breast biopsy and healthy breast tissue of healthy individuals who underwent breast biopsy due to benign lesions were used...
March 29, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38542313/overexpression-of-rest-represses-the-epithelial-mesenchymal-transition-process-and-decreases-the-aggressiveness-of-prostate-cancer-cells
#12
JOURNAL ARTICLE
Sebastián Indo, Octavio Orellana-Serradell, María José Torres, Enrique A Castellón, Héctor R Contreras
The RE-1 silencing transcription factor (REST) is a repressor factor related to neuroendocrine prostate cancer (PCa) (NEPC), a poor prognostic stage mainly associated with castration-resistant PCa (CRPC). NEPC is associated with cell transdifferentiation and the epithelial-mesenchymal transition (EMT) in cells undergoing androgen deprivation therapy (ADT) and enzalutamide (ENZ). The effect of REST overexpression in the 22rv1 cell line (xenograft-derived prostate cancer) on EMT, migration, invasion, and the viability for ENZ was evaluated...
March 15, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38528654/cd44-and-cd133-protein-expression-might-serve-as-a-prognostic-factor-for-early-occurrence-castration-resistant-prostate-cancer
#13
JOURNAL ARTICLE
Yayi Dwina, Litta Septina Mahmelia Zaid, Meilania Saraswati, Lisnawati Rachmadi, Aria Kekalih, Nur Rahadiani, Melva Louisa, Hasrayati Agustina, Chaidir Arif Mochtar, Agus Rizal Ardy Hariandy Hamid
BACKGROUND: The occurrence of castration-resistant prostate cancer (CRPC) varies in patients with advanced prostate cancer (PCa) undergoing androgen deprivation therapy (ADT). The rate of occurrence of CRPC may be related to the presence of prostate cancer stem cells (CSC). Thus, this study aims to evaluate the presence of CSC markers (CD44 and CD133) in histopathology tissue at the time of diagnosis and their correlation with the occurrence of CRPC in patients with advanced PCa within 2 years of ADT...
March 25, 2024: Prostate
https://read.qxmd.com/read/38523017/three-and-seven-month-prostate-specific-antigen-levels-as-prognostic-markers-for-overall-survival-in-metastatic-hormone-sensitive-prostate-cancer-results-from-swog-s1216-a-phase-3-randomized-trial-of-androgen-deprivation-plus-orteronel-or-bicalutamide
#14
JOURNAL ARTICLE
Mamta Parikh, Catherine Tangen, Maha H A Hussain, Shilpa Gupta, Sam Callis, Yeonjung Jo, Andrea Harzstark, Channing J Paller, Saby George, Matthew R Zibelman, Heather H Cheng, Benjamin L Maughan, Jingsong Zhang, Russell K Pachynski, Alan H Bryce, Daniel W Lin, David I Quinn, Seth P Lerner, Ian M Thompson, Tanya B Dorff, Primo N Lara, Neeraj Agarwal
BACKGROUND: A robust decrease in prostate-specific antigen (PSA) in response to androgen deprivation therapy (ADT) has been evaluated as a prognostic factor in patients with metastatic hormone-sensitive prostate cancer (mHSPC) since 2006, but the treatment of mHSPC has since evolved to include intensified therapy. OBJECTIVE: We assessed the association of PSA levels at 3 (PSA-3mo) and 7 (PSA-7mo) mo with overall survival (OS) in patients with mHSPC treated with ADT combined with either bicalutamide or orteronel in the S1216 phase 3 clinical trial...
March 23, 2024: European Urology Oncology
https://read.qxmd.com/read/38519296/a-prognostic-index-derived-from-lasso-selected-preoperative-inflammation-and-nutritional-markers-for-non-muscle-invasive-bladder-cancer
#15
JOURNAL ARTICLE
Dengxiong Li, Ruicheng Wu, Jie Wang, Junjiang Ye, Qingxin Yu, Dechao Feng, Ping Han
BACKGROUND: There is an urgent need to identify a robust predictor for BCG response in patients with non-muscle-invasive bladder cancer (NMIBC). We aimed to employ the Lasso regression model for the selection and construction of an index (BCGI) utilizing inflammation and nutrition indicators to predict the response to BCG therapy. METHODS: After acquiring the ethics approval, we searched the electric medical records in our institution and performed data screening...
February 29, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38510027/identification-of-cell-differentiation-trajectory-related-gene-signature-to-reveal-the-prognostic-significance-and-immune-landscape-in-prostate-cancer-based-on-multiomics-analysis
#16
JOURNAL ARTICLE
Liangxue Sun, Zhouting Tuo, Xin Chen, Huming Wang, Zhaojie Lyu, Guangyuan Li
BACKGROUND: In the context of prostate cancer (PCa), the occurrence of biochemical recurrence (BCR) stands out as a pivotal factor significantly impacting prognosis, potentially leading to metastasis and mortality. However, the early detection of BCR poses a substantial challenge for PCa patients. There is an urgent need to pinpoint hub genes that can serve as predictive indicators for BCR in PCa patients. METHODS: Our primary goal was to identify cell differentiation trajectory-related gene signature in PCa patients by pseudo-time trajectory analysis...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38502243/disabled-2-a-versatile-tissue-matrix-multifunctional-scaffold-protein-with-multifaceted-signaling-unveiling-its-potential-in-the-cancer-battle
#17
REVIEW
Nidhi N Shah, Bhavarth P Dave, Kashvi C Shah, Disha D Shah, Kunal G Maheshwari, Mehul R Chorawala, Priyajeet S Parekh, Maharsh Jani
A multifunctional scaffold protein termed Disabled-2 (Dab2) has recently gained attention in the scientific community and has emerged as a promising candidate in the realm of cancer research. Dab2 protein is involved in a variety of signaling pathways, due to which its significance in the pathogenesis of several carcinomas has drawn considerable attention. Dab2 is essential for controlling the advancement of cancer because it engages in essential signaling pathways such as the Wnt/β-catenin, epidermal growth factor receptor (EGFR), and transforming growth factor-beta (TGF-β) pathways...
March 19, 2024: Naunyn-Schmiedeberg's Archives of Pharmacology
https://read.qxmd.com/read/38481910/remission-depth-in-metastatic-hormone-sensitive-prostate-cancer-is-associated-with-prognosis-in-patients-with-initial-prostate-specific-antigen-values-above-100-ng-ml
#18
JOURNAL ARTICLE
Takeshi Azuma, Akimasa Katsumata, Masato Kano, Koji Tsumura
INTRODUCTION: Recently, new drugs have caused a paradigm shift in the treatment of metastatic hormone-sensitive prostate cancer (HSPC). Meanwhile, research has identified several prognostic factors of metastatic HSPC. OBJECTIVE: The present study focused on remission depth in metastatic HSPC and evaluated its association with remission depth. METHOD: We analyzed 427 patients diagnosed with metastatic HSPC with serum initial prostate-specific antigen (PSA) > 100 ng/ml...
February 2024: Curēus
https://read.qxmd.com/read/38473264/ubiquitin-b-ubiquitin-c-and-%C3%AE-catenin-as-promising-diagnostic-and-prognostic-tools-in-prostate-cancer
#19
JOURNAL ARTICLE
Daria Piątkowska, Anna Klimaszewska-Wiśniewska, Alicja Kosińska, Radosław Wujec, Dariusz Grzanka, Justyna Durślewicz
Prostate cancer (PC) is a major global public health concern, imposing a significant burden on men and ranking as the second most prevalent malignancy. This study delves into the intricate world of ubiquitination processes and expression regulation, with a specific focus on understanding the roles of ubiquitin B (UBB), ubiquitin C (UBC), and β-Catenin in PC development. We thoroughly analyze the expression profiles of UBB, UBC, and β-Catenin, investigating their interactions and associations with clinical and histopathological data...
February 23, 2024: Cancers
https://read.qxmd.com/read/38458890/identification-of-genes-with-rare-loss-of-function-variants-associated-with-aggressive-prostate-cancer-and-survival
#20
JOURNAL ARTICLE
Edward J Saunders, Tokhir Dadaev, Mark N Brook, Sarah Wakerell, Koveela Govindasami, Reshma Rageevakumar, Nafisa Hussain, Andrea Osborne, Diana Keating, Artitaya Lophatananon, Kenneth R Muir, Burcu F Darst, David V Conti, Christopher A Haiman, Antonis C Antoniou, Rosalind A Eeles, Zsofia Kote-Jarai
BACKGROUND: Prostate cancer (PrCa) is a substantial cause of mortality among men globally. Rare germline mutations in BRCA2 have been validated robustly as increasing risk of aggressive forms with a poorer prognosis; however, evidence remains less definitive for other genes. OBJECTIVE: To detect genes associated with PrCa aggressiveness, through a pooled analysis of rare variant sequencing data from six previously reported studies in the UK Genetic Prostate Cancer Study (UKGPCS)...
March 7, 2024: European Urology Oncology
keyword
keyword
98461
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.